Batimastat matrix metalloproteinase inhibitor data

BBIOY (Oxford, U.K.) presented results of a Phase I/II U.K. trial, showing safety and an early indication of efficacy, at the 8th U.S. National Cancer Institute and European Organization for Research and Treatment of Cancer Symposium on New Drugs in Cancer Therapy in Amsterdam.

Of the 15 patients enrolled, three receiving each of five dose levels, 12 did not require draining of ascites fluid for at least four weeks. No reaccumulation of fluid was found in seven patients, for a median of 75 days. Blood levels of the agent were maintained for four weeks by a single intraperitoneal injection. ...